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Nowadays magnetic resonance imaging is used for anatomical assessment of human brain structures in neu-
rodegenerative disorders causing brain atrophy for instance in multiple sclerosis (MS) or in Alzheimer Disease.
Pathological brain tissue loss can be described in terms of change in the brain parenchymal fraction (BPF).
This work shows the impact of segmentation method in SPM12 and additional segmentation in Computational
Anatomy Toolbox (CAT12) on calculated BPF value for patients suffer from with MS no treated and treated with
disease-modifying drug (DMD) interferon-beta (INFb) for one year and two years. Both methods confirm that
brain parenchymal fraction decreases with age, nevertheless for patients not treated INFb decreases faster than for
treated. An usability of Lesion Segmentation Tool toolbox in process of automatic detection and segmentation T2
hyperintense lesions in FLAIR images is discussed.
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1. Introduction
Presently multiple sclerosis (MS) is one of the most
common demyelinating diseases of central nervous sys-
tem (CNS), which progressively reduce Patients qual-
ity of life by a gradual loss of brain tissue. The be-
ginning of MS is often unexpected. The most common
first symptoms of the disease are i.e. paresthesias, im-
paired coordination, visual impairment or weakness of
muscles [1, 2]. This chronic, inflammatory disease can
occur in four types, which differ in the course of the dis-
ease: secondary progressive MS, primary progressive MS,
progressive-relapsing MS and the most common form
relapsing-remitting MS [2]. To slow down the progres-
sion of the disease, drug therapies currently used which
the main purpose are speeding recovery after MS re-
lapse, slowing the progression of the disease and man-
aging symptoms [3].
According to the data presented by the European Mul-
tiple Sclerosis Platform (EMSP) in Poland living at least
45,000 people with MS (population 38.5 million) [4]. It
mainly concerns young people and becomes a social prob-
lem requiring early diagnosis and treatment.
One of the diagnostic methods which revolutionised the
diagnosis of MS is magnetic resonance imaging (MRI).
Depending on the applied MRI sequences we have ability
to image demyelinating plaques as: hypointense lesions
and hyperintense lesions in anatomic T1 images and dif-
fusion – weighted imaging (DWI), respectively [5]. The
Apparent Diffusion Coefficient Maps (ADC) are also use-
ful for the quantitative assessment of pathological states
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of the brain, characterisation of lesions [6]. Moreover, ap-
plication of Gadolinium-based contrast agent allows find
active lesions in T1 sequence [5].
Diagnostic of MS is focused on changes in white matter
(WM), which are the most recognizable and specific for
these disease unit. However, in multiple sclerosis grey
matter is also destroyed but changes of cortical lesions
are harder to detect. Recently it was reported, it is pos-
sible to imaging grey matter (GM) plaques using Dou-
ble Inversion Recovery sequence (DIR) which supressing
signal from white matter and cerebrospinal fluid (CSF)
increases to a large degree intracortical lesion detection
compared to lesion identification on T2 and FLAIR se-
quence [7, 8].
Magnetic resonance imaging is useful not only in the
anatomical evaluation of human brain structures in neu-
rodegenerative disorders of the CNS but also in the quan-
titative assessment of pathological brain tissue loss de-
scribed by brain parenchymal fraction (BPF). BPF is de-
fined as ratio between brain parenchymal volume (BPV)
and intracranial volume (ICV), where BPV is a sum of
WM and GM, while ICV is as sum of BPV and cere-
brospinal fluid (CSF). Brain parenchymal fraction can
be specified using different programs such as SPM, VBM,
SIENAX and others but they can give different BPF val-
ues [9, 10].
In brain MRI, segmentation of brain tissues is an im-
portant step for numerical application. In this work we
investigate an influence of segmentation method used in
SPM12 and additional segmentation in Computational
Anatomy Toolbox (CAT12) on calculation of BPF. More-
over usability of Lesion Segmentation Tool (LST) toolbox
for SPM in process of automatic detection and segmen-
tation T2 hyperintense lesions in FLAIR images is dis-
cussed.
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2. Materials and Methods
2.1 Experimental
The retrospective analysis of MRI brain images were
performed on 34 patients with diagnosed multiple sclero-
sis (ICD-10, G35). Patients were divided into two groups.
The first consist of 25 females of age ranging from 25-59
and 9 females of age ranging from 22–44 treated with
disease-modifying drug (DMD) interferon-beta (INFb)
for one year and two years. Brain images were regis-
tered with 1,5 T MAGNETOM Aera scanner (Siemens,
Erlangen, Germany) and 1.5 T GE scanner Signa HDx in
Helimed Diagnostic Imaging Center for not-treated pa-
tients and for treated with INFb, respectively. The stud-
ies were performed as part of normal clinical work using
protocol adapted to imaging MS containing sequences i.e.
FLAIR and T1.
2.2 Methods of BPF determination
To calculate volumes of white matter, grey matter and
cerebrospinal fluid segmentation of MRI images must
be performed. For this purpose SPM12 (Statistical
Parametric Mapping, Institute of Neurology, London)
in MATLAB (MathWorks, Inc.) environment and an
extension to SPM package - CAT12 (C. Gaser, Struc-
tural Brain Mapping group, Jena University Hospital,
Jena, Germany) which provide voxel-based morphome-
try (VBM) were used. Brain parenchymal and intracra-
nial volumes for SPM12 were estimated using script [11],
while in CAT12 function ‘Estimate TIV’ was used.
2.3 MS Lesion segmentation tool
Demyelinating hyperintense T2 lesions were seg-
mented by the lesion growth algorithm (LGA) [12]
as implemented in LST toolbox version 2.0.11
(http://www.applied-statistics.de/lst.html) for SPM12
package in MATLAB. The algorithm first segmented
the T1 – weighted images into the three main tissue
classes (WM, GM and CSF). Then this information
was combined with coregistered FLAIR intensities in
order to calculate lesion belief maps. Threshold value
(κ  0.1) was chosen for LGA [8].
2.4 Statistics
Analysis of variance (ANOVA) was used to examine
the variance of a dependent variable and Pearson corre-
lation tests were used to determine correlations between
the variables. The significance level was set to p   0.05.
3. Results and discussion
Demyelinating process in multiple sclerosis is charac-
terized by disintegration of myelin sheaths. The most
common location of plaques is white matter of both hemi-
spheres of the brain, mainly periventricular, ventricles,
juxtacortical (see Fig. 1) and corpus callosum and tem-
poral lobe are also involvement depending on the mor-
phology of demyelinating lesions [1].
Fig. 1. a) The original FLAIR image. b) Overlayed
lesion probability map (κ  0.1) on FLAIR image high-
lighting white matter lesions: adjacent to the ventricles
(v), periventricular (p) and juxtacortical (j).
TABLE I
The number and volume of demyelinating white mat-
ter plaques for representative patients not treated with
interferon-beta calculated in LST for initial threshold
(κ  0.1) and default vaule of MRF (1) and maximum
iterations (50).
ID Age [y] WM [ml]
Number WM [ml]
% of WM
of plaques
1 25 482.47 5 0.81921 0.17
2 31 561.83 6 0.39101 0.07
3 34 612.76 65 9.16670 1.50
4 37 455.57 17 4.66160 1.02
5 45 435.86 6 0.25558 0.06
6 46 453.91 25 0.90027 0.20
7 46 487.38 12 0.81348 0.17
8 49 437.08 30 2.6493 0.61
Figure 2. shows the BPF of MS patients as a func-
tion of age. The linear regression confirms of brain at-
rophy with increasing age according to expectation. It
is noteworthy the negative moderate Pearson correlation
in CAT12 and SPM12 were obtained (r  0.41). For
FLAIR sequence Person’s correlation for untreated pa-
tients is also negative moderate (r  0.45). For patients
treated with interferon-beta this correlation is weaker
(after one year r  0.36 and two years r  0.28),
probably due to less numerous group. The linear fits
for patients treated with INFb for one year as well as
two years (Fig. 2b.) are nearly the same and show only
slightly smaller slope in comparison with patients not
treated and also difference between them are not statis-
tically significant. These fits are within the limits of error
which is very big because of little number of patients as
well as large inter-individual variation among them.
In order to make the SM diagnosis easier, LST calcu-
lating the amount and volume of demyelinating changes
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Fig. 2. BPF values in relation to age with linear fit
of data. a) BPF calculated for T1-weighted sequence
for two toolboxes CAT12 and SPM12 for untreated MS
patients. b) BPF calculated for FLAIR sequence in
SPM12 for patients not treated and treated interferon-
beta for one year and two years, respectively.
can be applied. Sample calculations for MS patients are
presented in Table I.
Basing on the data in Table I, one can see that volume
of white matter plaques constitute a low percentage of
white matter. Nevertheless, they lead to gradual deteri-
oration of quality of life including disability.
It is noteworthy that lesion probability map on FLAIR
image (Fig. 1) highlighted demyelinating changes. Auto-
matic lesion segmentation greatly simplifies work, but it
is essential to draw attention to appropriate selection of
parameters i.e. initial thresholds (κ). Choosing a low
κ-value we get a small number of white matter plaques
while for the high κ we can get result with large number
of lesion, but some of them could be artefacts.
4. Final remarks
Magnetic resonance studies of multiple sclerosis pa-
tients are important part of diagnostic of this disease.
Based on MRI data it is possible to specify additional
quantitative parameters, which increases diagnostics of
MS and monitoring of applied therapy.
It should be noted that brain parenchymal fraction al-
lows for quantitative estimation of brain atrophy. Gener-
ally decrease of BPF with age in patients suffer from MS
is higher in comparison with healthy individuals [13,9].
Unfortunately value of BPF depends on use of calcula-
tion method. Therefore, it is necessary to develop gold
standard of BPF determination to provide a proper com-
parison and discussion regarding brain atrophy.
Lesion Segmentation Tool seems to be very useful in
diagnostic of disease progress because allows for calculat-
ing the number and volume of demyelinating plaques but,
it is essential to draw attention to appropriate selection
of parameters i.e. initial thresholds (κ).
Furthermore, it is shown that use of DMD such as
interferon–beta in multiple sclerosis treatment slightly
inhibits disease progression, however studies on larger re-
search group is needed.
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